로딩 중…
지수 로딩 중…
Optipharm.CO.,LTD
153710· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,710-0.32%
2026-09-18
Financials
Valuation Metrics
Optipharm.CO.,LTD's Market Cap is ₩691B. At end of 2025 it was ₩748B. Ranked #1556 of 2,421 in KR market (top 64%), #913 of 1,640 on KOSDAQ (top 56%), #173 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.10B KRW | KR#1,556/2,421 Sec#173/231 |
| Revenue | 23.59B KRW | KR#2,105/2,421 Sec#150/231 |
| Net Income | -1.86B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 40.77B KRW | KR#2,278/2,421 Sec#208/231 |
| Net Assets | 25.40B KRW | KR#2,221/2,421 Sec#203/231 |
| Employees | 77 | KR#1,826/2,421 Sec#155/231 |
| Value | ||
| P/B | 2.72x | KR#2,079/2,421 Sec#163/231 |
| P/S | 2.93x | KR#1,975/2,421 Sec#122/231 |
| FCF Yield | -5.88% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -7.33% | KR#1,874/2,421 Sec#136/231 |
| ROA | -4.57% | KR#1,916/2,421 Sec#137/231 |
| Op. Margin | -7.53% | KR#1,932/2,421 Sec#129/231 |
| Revenue Growth | 11.84% | KR#814/2,421 Sec#81/231 |
| Financial Health | ||
| Debt Ratio | 60.51% | KR#1,102/2,421 Sec#131/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -4.06B KRW | KR#1,455/2,421 Sec#114/231 |
| Cash | 2.28B KRW | KR#2,224/2,421 Sec#211/231 |
| Current Ratio | 1.16x | KR#1,541/2,421 Sec#158/231 |
| Performance | ||
| 1Y Return | -10.11% | KR#977/2,421 Sec#62/231 |
| 1M Return | -1.88% | KR#1,463/2,421 Sec#113/231 |
| From 52W High | -24.64% | KR#374/2,421 Sec#19/231 |
| 1Y MDD | -31.29% | KR#288/2,421 Sec#19/231 |
| Trading | ||
| Volume | 1,221 shares | KR#2,312/2,421 Sec#223/231 |
| Trading Value | 5.7M KRW | KR#2,329/2,421 Sec#222/231 |
| Foreign Own. | 0.83% | KR#2,092/2,421 Sec#204/231 |
| Per Share | ||
| EPS | -127 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,731 KRW | KR#2,133/2,421 Sec#178/231 |
Company Info
OptiPharm, established in 2000 and listed on KOSDAQ in 2018, specializes in animal-related businesses, including disease diagnosis, pharmaceuticals, and bacteriophage. Since 2006, it has developed an independent disease appraisal system and diagnostic products. Leveraging original technologies like transgenic technology and animal-related infrastructure, the company is expanding into human-related ventures such as bacteriophage-based disease treatments and xenotransplantation development.